Neotherapeutics takes a charge in loss
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
NeoTherapeutics Inc., an Irvine developer of treatments for neurological and psychiatric diseases, reported a second quarter net loss of $12.3 million, or $1.29 a share, which included a
$1-million noncash accounting charge related to the sale of debentures. The net loss for the prior year totaled $4.1 million, or 63 cents a share. No revenue was recorded. The company
attributed the wider losses to higher expenses related to its human clinical trial for Neotrofin, a potential treatment for Alzheimer’s disease. MORE TO READ